A Medical Device Daily
Aisling Capital (New York) said that it raised $650 million in committed capital for its newest life sciences fund, Aisling Capital III LP.
Aisling will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry.
"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," said Dennis Purcell, senior managing partner of Aisling Capital. "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."
Aisling Capital is a life sciences private equity firm with more than $1.6 billion under management.